COVID-19 Infusion Therapy HCPCS Code range Q0220-Q0249

The HCPCS codes range COVID-19 Infusion Therapy Q0220-Q0249 is a standardized code set necessary for Medicare and other health insurance providers to provide healthcare claims.

Subscribe to Codify and get the code details in a flash.

HCPCS Code Range Q0220-Q0249

Q0220-Q0249 COVID-19 Infusion Therapy
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
Injection, bebtelovimab, 175 mg
Injection, casirivimab and imdevimab, 600 mg
Injection, casirivimab and imdevimab, 2400 mg
Injection, casirivimab and imdevimab, 1200 mg
Injection, bamlanivimab and etesevimab, 2100 mg
Injection, sotrovimab, 500 mg
Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg